Mumbai: Eli Lilly and Company announced plans to invest more than $1 billion over the coming years to expand contract manufacturing operations in India. The investment aims to enhance global medicine supply capacity and increase access to the company’s medicines worldwide.
As part of the initiative, Lilly will establish a new Manufacturing and Quality hub in Hyderabad. The facility will provide technical capabilities and oversight for the company’s contract manufacturing network across India. Recruitment for roles including engineers, chemists, analytical scientists, quality professionals, and management positions will begin immediately.
Patrik Jonsson, Executive Vice President and President of Lilly International, said the investment underscores the company’s confidence in India as a center for manufacturing capability within its global network. “Working with trusted contract manufacturers expands our capabilities to deliver life-changing medicines at greater scale — with quality always at the core,” he said.
Telangana Chief Minister A. Revanth Reddy said Lilly’s expansion strengthens Hyderabad’s position as a center for global healthcare innovation. Information Technology and Industries Minister Sridhar Babu noted that the project reflects Telangana’s growth in advanced healthcare manufacturing.
Nivruti Rai, Managing Director and CEO of Invest India, said the investment demonstrates both India’s competitiveness as a global manufacturing hub and Lilly’s commitment to innovation and healthcare advancement.
Lilly has invested more than $55 billion globally since 2020 to expand manufacturing capacity and support new medicines in areas including diabetes, obesity, Alzheimer’s disease, cancer, and autoimmune conditions. The new investment reinforces the company’s presence in India, where it operates sites in Gurugram, Bengaluru, and Hyderabad.
